Company profile
Your Gastrointestinal Research Partner GI Expertise | Gut Models | Human Trials
Aelius Biotech Limited is a UK company with status active founded in 2018 based in North East England.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
AA | Transaction MzUyNzMxNjQzMWFkaXF6a2N4
Published 19 Jun 2026 11:56
Next confirmation statement due date
RESOLUTIONS | Transaction WUVZUjRFN0VhZGlxemtjeA | Paper/PDF filed
Published 11 Apr 2026 22:38
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQzNDY0MzMyM2FkaXF6a2N4
Published 05 Sep 2024 13:16
Company registered at Companies House
Aelius Biotech develops models of parts of the human body for research purposes.
Aelius Biotech specialise in lab models of the aerodigestive tract. Our predictive systems can help you understand your formulation during vital pre-clinical stages to help you improve and de-risk product development and get successful products to market.
Data from the MGS showed that alginate is released in the small intestinal phase- the major site of lipase activity and significantly reduced fat digestion. The in vitro data built a solid evidence base for subsequent in vivo human studies. After a successful acceptability study a pilot human proof of principle study then went on to demonstrate that alginate bread can reduce the level of circulating triglycerides in plasma after a meal as well as significantly increase the level of fat in ileal effluent. Jon Farrimond. Scientific and Regulatory Affairs Suntory Beverage and Food (Europe) - "We have worked with Aelius Biotech on the development of two products that have gone to human trials to support EFSA health claims and have seen the value that reliable in vitro models can provide. The model has helped us make numerous key decision and investments. I am sure these models will be used by industry to accelerate and improve product development." Aelius Biotech has received £2 million pounds in investment to date.
Data from the MGS showed that alginate is released in the small intestinal phase- the major site of lipase activity and significantly reduced fat digestion. The in vitro data built a solid evidence base for subsequent in vivo human studies. After a successful acceptability study a pilot human proof of principle study then went on to demonstrate that alginate bread can reduce the level of circulating triglycerides in plasma after a meal as well as significantly increase the level of fat in ileal effluent. Jon Farrimond. Scientific and Regulatory Affairs Suntory Beverage and Food (Europe) - "We have worked with Aelius Biotech on the development of two products that have gone to human trials to support EFSA health claims and have seen the value that reliable in vitro models can provide. The model has helped us make numerous key decision and investments. I am sure these models will be used by industry to accelerate and improve product development."
1 Oct 2023 to 31 Dec 2024
Cultivated meat promises to revolutionize the food industry by providing a more ethical and greener alternative to animal products, whilst retaining the same taste and texture. However, these products are being held back by the technical complexity of production and, in particular, the high cost of materials used in their manufacture. It is estimated that...
1 Apr 2022 to 31 Mar 2024
This project aims to assess the feasibility of scaling up production of a 'Colon Kit' a research model of the human large intestine. This will meet the pressing need for effective and affordable models of the human large intestine for research and personalised medicine. This product can provide an accessible, and affordable cutting edge research tool for ...
